Breaking News: Higher Dose of Wegovy Ups Weight Loss but Side Effects
A recent trial has revealed that a higher weekly dose of Wegovy, a medication used to treat obesity and type 2 diabetes, achieves greater weight loss than the standard amount. However, this increased efficacy comes with a higher risk of side effects.
Key Findings:
A higher weekly dose of Wegovy resulted in an average weight loss of 18% over a year, compared to 15% with the standard dose.
The trial involved over 2,000 participants and was conducted by pharmaceutical firm Novo Nordisk.
Side effects were more common among those receiving the higher dose, including nausea, vomiting, and diarrhea.
Timeline:
The trial began in 2019 and concluded in 2021.
Results were published in a peer-reviewed journal earlier this week.
Wegovy has been approved to treat obesity and type 2 diabetes since 2020.
Immediate Impact and Response:
Healthcare professionals are urging caution when prescribing the higher dose of Wegovy, citing the increased risk of side effects. Patients who have responded well to the standard dose may still benefit from the higher dose, but careful monitoring is essential.
Background Context:
Wegovy works by mimicking a hormone called GLP-1, which helps regulate appetite and metabolism. It has been shown to be effective in promoting weight loss when combined with diet and exercise.
What Happens Next:
The trial results will likely influence prescribing practices for Wegovy, with healthcare professionals weighing the benefits of greater weight loss against the increased risk of side effects. Further research is needed to fully understand the implications of these findings and to develop more effective treatments for obesity.
*This story is developing. Information compiled from Newscientist reporting.*
